Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers

Cell Syst. 2021 Sep 22;12(9):907-923.e6. doi: 10.1016/j.cels.2021.07.002. Epub 2021 Aug 5.

Abstract

eIF4F plays diverse roles in human cancers, which complicate the development of an overarching understanding of its functional and regulatory impacts across tumor types. Typically, eIF4F drives initiation from the mRNA 5' end (cap) and is composed of eIF4G1, eIF4A1, and cap-binding eIF4E. Cap-independent initiation is possible without eIF4E, from internal ribosomal entry sites (IRESs). By analyzing large public datasets, we found that cancers selectively overexpress EIF4G1 more than EIF4E. That expression imbalance supports EIF4G1 as a prognostic indicator in patients with cancer. It also attenuates "housekeeping" pathways that are usually regulated in a tissue-specific manner via cap-dependent initiation in healthy tissues and reinforce regulation of cancer-preferred pathways in cap-independent contexts. Cap-independent initiation is mechanistically attributable to eIF4G1 hyperphosphorylation that promotes binding to eIF4A1 and reduced eIF4E availability. Collectively, these findings reveal a novel model of dysregulated eIF4F function and highlight the clinical relevance of cap-(in)dependent initiation in cancer.

Keywords: RNA-sequencing; cap-independent translation initiation; computational analysis; eIF4F; eukaryotic initiation factor; human cancers; prognostic gene expression; protein interaction; translation dysregulation; translation initiation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Eukaryota / genetics
  • Eukaryota / metabolism
  • Eukaryotic Initiation Factor-4F* / genetics
  • Eukaryotic Initiation Factor-4F* / metabolism
  • Eukaryotic Initiation Factor-4G / genetics
  • Eukaryotic Initiation Factor-4G / metabolism
  • Humans
  • Neoplasms* / genetics
  • Protein Biosynthesis

Substances

  • Eukaryotic Initiation Factor-4F
  • Eukaryotic Initiation Factor-4G